To the Editor We agree with Mr Hakim and Dr Ross1 that biosimilars in the United States are unlikely to yield widely expected cost savings and proffer an additional explanation: the frequency and complexity of biosimilar-related patent litigation have thus far resulted in too few marketed biosimilars.2 Only 2 of the 5 biosimilars approved by the US Food and Drug Administration (FDA) are now commercially available. As noted in the Viewpoint, prices for small molecule drugs drop 70% to 90% following generic approval, but these savings reflect competition after the entry of multiple generics, which is unlikely to occur anytime soon with biosimilars.3
Chen B, Yang YT, Bennett CL. Challenges to Biosimilar Substitution. JAMA. 2017;318(12):1186. doi:10.1001/jama.2017.11930
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: